VALENTIM, Alícia Pessoa.
Resumo:
Epilepsy is considered a neurological disorder that affects people of any age group, it is
estimated that about 65 million people worldwide live with this disease, according to the
World Health Organization (WHO). Cannabis sativa, or popularly known as marijuana,
has therapeutic applications and its use for medical purposes has been increasingly
studied. Preclinical research demonstrates that Cannabidiol (CBD) has several
therapeutic effects, such as anticonvulsant, anti-inflammatory, neuroprotective,
antipsychotic, antitumor and anxiolytic activity. Therefore, this research aims to review
the therapeutic potential of cannabidiol for the treatment of epilepsy. The present study
is an integrative review, using data available on the internet in the VHL, LILACS and
Scielo databases. For the search, systematized descriptors were used through Boolean
operators with the following strategy: “Epilepsy AND Cannabidiol”. This research
included original or complete review articles on the subject, published in the period
from 2013 to 2023, only materials in Portuguese and studies that did not investigate the
proposed subject, articles with paid access, temporal margin greater than ten years and
lack of correlation with the theme. From this research, 33 results were found, which
consequently resulted in an evaluation, in which 05 studies were selected for the
production of this work. The use of CBD as an adjuvant therapy proves to be an
alternative where it provides a reduction in crises, better conditions and quality of life
for patients, however it is not yet an eligible drug to be incorporated into the SUS.
Despite the promising potential of CBD, there are many therapeutic problems
surrounding its use, such as the knowledge of its pharmacodynamics and its use in
crises. Also about the continuous use for certain syndromes, occurrence of drug
interactions, risk of adverse effects and lack of standardized therapeutic guidelines for
its clinical use.
